As per the research conducted by GME, the Tuberculosis Therapeutics Market will grow with a CAGR value of 6 percent by 2026. Due to increasing tuberculosis prevalence, growing government initiatives for tuberculosis knowledge & understanding, effective cooperation amongst educational & corporate players for innovative drug production, and soaring incidence of MDR and XDR cases in both developed & developing countries are catapulting the market's expansion.
Browse 151 Market Data Tables and 111 Figures spread through 181 Pages and in-depth TOC on “Tuberculosis Therapeutics Market - Forecast to 2026"
By Disease Type (Active TB and Latent TB), By Therapy (First-Line and Second-Line), By Region (North America, Asia Pacific, CSA, Europe, and The Middle East and Africa); End-User, Landscape, Company Market Share Analysis, and Competitor Analysis
Key Market Insights
· The growing volume of drug inventions along with the increasing number of respiratory organ diseases are driving the market.
· Active tuberculosis (ATB) segment is likely to dominate the market due to a surge in the volume of DS and MDR TB cases.
· Due to the cost-intensive layout of MDR TB products, second-line therapy is presumed to lead in this market.
· Due to the growing understanding of tuberculosis and its effects on human health, North America holds a significant share of the tuberculosis therapeutic market.
· Lupin, Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson & Johnson (J&J) Services, Novartis AG, Sigma Pharmaceutical Pvt. Ltd., Aventis Pharmaceuticals Ltd., Hoffmann-La Roche Ltd., VersaPharm Inc., Sanofi Aventis, and Bayer among others, are the top players in the tuberculosis therapeutics market.
Browse the Report @ https://www.globalmarketestimates.com/market-report/global-tuberculosis-therapeutics-market-3134
Disease Type Outlook (Revenue, USD Billion, 2021-2026)
· Active TB
· Latent TB
Therapy Outlook (Revenue, USD Billion, 2021-2026)
Regional Outlook (Revenue, USD Billion, 2021-2026)
Rest of Europe
Rest of APAC
Central & South America
Rest of CSA
Middle East & Africa
Rest of MEA
Contact: Tracy Simon
Email address: email@example.com
Phone Number: +16026667238
Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php
Next-Gen Expertise About Us
Tuberculosis Therapeutics Market Insights
Tuberculosis is triggered by a bacterium named Mycobacterium tuberculosis whose primary area of
infection is the lungs but may often damage other organs of the body. The basic way of transmission
of Tuberculosis is via the air; when a person infected with Tuberculosis comes into contact with
another person, this leads to the transmission of the infection by talking, coughing, or sneezing. The
disease is quite fatal and needs on-time diagnosis & proper treatment or else the person can also
succumb to the disease. The symptoms of this disease are excessive cough, weight loss, fever,
insomnia, and vomiting. If a patient is suffering from these symptoms, then in order to treat the
patient on time, the diagnosis has to be done immediately, which can be accomplished by various
tests such as, Chest X-Ray, Acid-Fast Bacillus (AFB) Tests, Testing for TB Infection, Tuberculin Skin
Testing, and Tuberculosis Screening.
According to the World Health Organization's 2020 Global Tuberculosis (TB) Study, 1.5 million
individuals died from tuberculosis in 2018. Tuberculosis is one of the top ten reasons for mortality
globally, and the main source trigger is by a specific infectious agent. Overall, the worldwide threat of
tuberculosis and multidrug-resistant tuberculosis poses a risk to prominent medical regulatory
organizations. The proactive participation of both the medical community & the government in
combating tuberculosis is likely to raise the volume of Tuberculosis diagnoses. This, in particular, it is
propelling the global tuberculosis therapeutics market, which is being fueled by the rising national and
international proliferation of TB and MDR-TB.
The rising prevalence of tuberculosis would provide attractive prospects for the global tuberculosis
therapeutics industry. As per the World Health Organization, about one-third of the global popul